UnknownNot Applicable

S100A8/A9 and Innate Immunity in Liver Disease

United Kingdom100 participantsStarted 2021-09-28

Plain-language summary

This observational study evaluates the concentration of immune protein S100A8/A9 in different liver failure syndromes, its interaction with the immune system and validity as an immunotherapeutic target to improve survival in patients with advanced cirrhosis and/or acute on chronic liver failure.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Presence of chronic liver disease, or cirrhosis due to any aetiology (latter based upon a histopathological diagnosis or compatible laboratory data and radiological findings)
✓. Acute alcoholic hepatitis (definition as per Crabb et al, 2016)35
✓. Acute liver failure due to any aetiology
✓. Acute-on-chronic liver failure (defined as per EASL-CLIF definition)17
✓. Intubated patients with liver disease in intensive care
✓. Undergoing a bronchoscopy or a non-directed broncho-alveolar lavage as part of their routine clinical care
✓. Absence of cirrhosis based on clinical, radiological or histopathological features, including patients with non-cirrhotic portal hypertension, cardiac ascites (ascites due to heart failure) or patients with chronic kidney disease undergoing continuous ambulatory peritoneal dialysis (CAPD)
✓. Presence of clinically significant ascites

What they're measuring

Concentration of plasma S100A8/A9

Timeframe: 1 years

Trial details

NCT IDNCT05793983

SponsorSt George's, University of London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-09-01

Contact for this trial

Arjuna Singanayagam, MBBS; PhD

02086729944 asingana@sgul.ac.uk

View on ClinicalTrials.gov More Cirrhosis, Liver trials